142 related articles for article (PubMed ID: 36529838)
1. Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study.
Smith JA; Anderson SJ; Harris KL; McGillen JB; Lee E; Garnett GP; Hallett TB
Lancet HIV; 2016 Jul; 3(7):e289-96. PubMed ID: 27365203
[TBL] [Abstract][Full Text] [Related]
2. The Price of Prevention: Cost Effectiveness of Biomedical HIV Prevention Strategies in South Africa.
Moodley N; Gray G; Bertram M
Clin Res HIV AIDS; 2016; 3(1):. PubMed ID: 28824960
[TBL] [Abstract][Full Text] [Related]
3. Modelling Methods of Economic Evaluations of HIV Testing Strategies in Sub-Saharan Africa: A Systematic Review.
Vasantharoopan A; Simms V; Chan Y; Guinness L; Maheswaran H
Appl Health Econ Health Policy; 2023 Jul; 21(4):585-601. PubMed ID: 36853553
[TBL] [Abstract][Full Text] [Related]
4. Costs of HIV prevention among out-of-treatment drug-using women: results of a randomized controlled trial.
Ruger JP; Ben Abdallah A; Cottler L
Public Health Rep; 2010; 125 Suppl 1(Suppl 1):83-94. PubMed ID: 20408391
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of the quality of trials evaluating biomedical HIV prevention interventions shows that many lack power.
Graham SM; Shah PS; Aesch ZC; Beyene J; Bayoumi AM
HIV Clin Trials; 2009; 10(6):413-31. PubMed ID: 20133272
[TBL] [Abstract][Full Text] [Related]
6. The role of economic evaluations in advancing HIV multipurpose prevention technologies in early-stage development.
Chapman K; Torres-Rueda S; Metzler M; Young Holt B; Kahn-Woods E; Thornton D; Gomez GB
Front Reprod Health; 2024; 6():1272950. PubMed ID: 38699591
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation and transferability of physical activity programmes in primary prevention: a systematic review.
Wolfenstetter SB; Wenig CM
Int J Environ Res Public Health; 2010 Apr; 7(4):1622-48. PubMed ID: 20617050
[TBL] [Abstract][Full Text] [Related]
8. Better Service by Doing Less: Introducing De-implementation Research in HIV.
McKay VR; Tetteh EK; Reid MJ; Ingaiza LM
Curr HIV/AIDS Rep; 2020 Oct; 17(5):431-437. PubMed ID: 32794070
[TBL] [Abstract][Full Text] [Related]
9. Bridging the Efficacy-Effectiveness Gap in HIV Programs: Lessons From Economics.
Bor J; Thirumurthy H
J Acquir Immune Defic Syndr; 2019 Dec; 82 Suppl 3(Suppl 3):S183-S191. PubMed ID: 31764253
[TBL] [Abstract][Full Text] [Related]
10. Drug Pricing, Patient Welfare, and Cost-Effectiveness Analysis.
van Baal P; Barros PP
Value Health; 2024 Mar; 27(3):271-272. PubMed ID: 38286248
[No Abstract] [Full Text] [Related]
11. A Tutorial on Net Benefit Regression for Real-World Cost-Effectiveness Analysis Using Censored Data from Randomized or Observational Studies.
Chen S; Bang H; Hoch JS
Med Decis Making; 2024 Apr; 44(3):239-251. PubMed ID: 38347698
[TBL] [Abstract][Full Text] [Related]
12. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
Stansfield SE; Heitner J; Mitchell KM; Doyle CM; Milwid RM; Moore M; Donnell DJ; Hanscom B; Xia Y; Maheu-Giroux M; Vijver DV; Wang H; Barnabas R; Boily MC; Dimitrov DT
J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26109. PubMed ID: 37439080
[TBL] [Abstract][Full Text] [Related]
13. What will it take for an injectable ARV to change the face of the HIV epidemic in high-prevalence countries? Considerations regarding drug costs and operations.
Meyer-Rath G; Jamieson L; Pillay Y
J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26106. PubMed ID: 37439062
[TBL] [Abstract][Full Text] [Related]
14. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.
Mitchell KM; Boily MC; Hanscom B; Moore M; Todd J; Paz-Bailey G; Wejnert C; Liu A; Donnell DJ; Grinsztejn B; Landovitz RJ; Dimitrov DT
Lancet Reg Health Am; 2023 Feb; 18():100416. PubMed ID: 36844011
[TBL] [Abstract][Full Text] [Related]
15. Implementation and resource needs for long-acting PrEP in low- and middle-income countries: a scoping review.
Castor D; Heck CJ; Quigee D; Telrandhe NV; Kui K; Wu J; Glickson E; Yohannes K; Rueda ST; Bozzani F; Meyers K; Zucker J; Deacon J; Kripke K; Sobieszczyk ME; Terris-Prestholt F; Malati C; Obermeyer C; Dam A; Schwartz K; Forsythe S
J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26110. PubMed ID: 37439063
[TBL] [Abstract][Full Text] [Related]
16. Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward.
Torres-Rueda S; Terris-Prestholt F; Gafos M; Indravudh PP; Giddings R; Bozzani F; Quaife M; Ghazaryan L; Mann C; Osborne C; Kavanagh M; Godfrey-Faussett P; Medley G; Malhotra S
Pharmacoeconomics; 2023 Jul; 41(7):787-802. PubMed ID: 36905570
[TBL] [Abstract][Full Text] [Related]
17. Costs and Cost-Effectiveness of Biomedical, Non-Surgical HIV Prevention Interventions: A Systematic Literature Review.
Bozzani FM; Terris-Prestholt F; Quaife M; Gafos M; Indravudh PP; Giddings R; Medley GF; Malhotra S; Torres-Rueda S
Pharmacoeconomics; 2023 May; 41(5):467-480. PubMed ID: 36529838
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
